Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua R Steinerman

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Neurology. Clinical Practice|June 23, 2022
Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple SclerosisAmber Salter, Gary Cutter, Ruth Ann Marrie, et al.
BMC Medicine|June 19, 2019
Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial dataFrancesca Bovis, Luca Carmisciano, Alessio Signori, et al.
Archives of Neurology|July 16, 2008
Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic studyJoshua R Steinerman, Michael Irizarry, Nikolaos Scarmeas, et al.
Annals of Neurology|September 5, 2018
Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areasFrancesca Bovis, Alessio Signori, Luca Carmisciano, et al.
International Journal of MS Care|January 17, 2022
A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple SclerosisAmber Salter, Robert J Fox, Gary Cutter, et al.
Multiple Sclerosis and Related Disorders|July 22, 2015
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosisJerry S Wolinsky, T Erik Borresen, Dennis W Dietrich, et al.
JMIR Mhealth and Uhealth|April 27, 2017
Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial EvaluationBrian M Iacoviello, Joshua R Steinerman, David B Klein, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data setMarcus W Koch, Gary R Cutter, Gavin Giovannoni, et al.
Disability and Rehabilitation|July 22, 2023
Development of an integrated conceptual model of multiple sclerosis spasticityMichelle H Cameron, Francois Bethoux, Edelle Field-Fote, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 30, 2021
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept TrialAleksandar Videnovic, Amy W Amara, Cynthia Comella, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Neurology. Clinical Practice|June 23, 2022
Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple SclerosisAmber Salter, Gary Cutter, Ruth Ann Marrie, et al.
BMC Medicine|June 19, 2019
Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial dataFrancesca Bovis, Luca Carmisciano, Alessio Signori, et al.
Archives of Neurology|July 16, 2008
Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic studyJoshua R Steinerman, Michael Irizarry, Nikolaos Scarmeas, et al.
Annals of Neurology|September 5, 2018
Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areasFrancesca Bovis, Alessio Signori, Luca Carmisciano, et al.
International Journal of MS Care|January 17, 2022
A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple SclerosisAmber Salter, Robert J Fox, Gary Cutter, et al.
Multiple Sclerosis and Related Disorders|July 22, 2015
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosisJerry S Wolinsky, T Erik Borresen, Dennis W Dietrich, et al.
JMIR Mhealth and Uhealth|April 27, 2017
Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial EvaluationBrian M Iacoviello, Joshua R Steinerman, David B Klein, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data setMarcus W Koch, Gary R Cutter, Gavin Giovannoni, et al.
Disability and Rehabilitation|July 22, 2023
Development of an integrated conceptual model of multiple sclerosis spasticityMichelle H Cameron, Francois Bethoux, Edelle Field-Fote, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 30, 2021
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept TrialAleksandar Videnovic, Amy W Amara, Cynthia Comella, et al.
Pageof 3